Trending...
- MainConcept Easy Video API Extends Full Transcoding to Arm and NETINT VPUs
- Black Women Living With, and Impacted by, HIV Express Gratitude, Grief, Joy, and Resilience
- New Online Board Game Sin of Angels Lets Outlaw Gangs Battle for LA Solo or With Friends
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) in which the two companies will work together to gather insights, discover novel drug targets, and aim to develop therapeutics for the broader oncology community. By combining the capabilities of a technology company with those of a biopharmaceutical company, the two companies hope to advance drug discovery and development, to more quickly deliver innovation to patients.
The strategic collaboration aims to optimize Tempus' AI-enabled platform and vast repository of multimodal data to advance novel therapeutic programs in oncology on a global scale. Under the terms of the agreement, AstraZeneca will leverage Tempus' de-identified data and analytical tools across a broad range of capabilities. This collaboration combines Tempus' AI and machine learning capabilities for identifying novel insights with AstraZeneca's deep expertise in R&D to ultimately develop new therapeutic options for patients.
More on illi News
"Artificial intelligence has the potential to advance precision medicine in ways that seemed unimaginable just a few short years ago," said Eric Lefkofsky, Founder and CEO of Tempus. "We look forward to working with AstraZeneca to apply AI-enabled solutions to advance its robust therapeutic pipeline in an effort to help patients live longer and healthier lives."
"Cancer drug discovery and clinical development are being transformed by the ability to analyze vast amounts of rich data using artificial intelligence," said Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca. "We are very pleased to collaborate with Tempus to enhance our data-driven R&D strategy and glean critical insights that will deepen our understanding of complex tumor biology, enhance access to predictive preclinical models, and increase the probability of clinical success across our diverse pipeline."
About Tempus
More on illi News
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Contacts
Erin Carron
erin.carron@tempus.com
The strategic collaboration aims to optimize Tempus' AI-enabled platform and vast repository of multimodal data to advance novel therapeutic programs in oncology on a global scale. Under the terms of the agreement, AstraZeneca will leverage Tempus' de-identified data and analytical tools across a broad range of capabilities. This collaboration combines Tempus' AI and machine learning capabilities for identifying novel insights with AstraZeneca's deep expertise in R&D to ultimately develop new therapeutic options for patients.
More on illi News
- Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
- Chicago: Mayor Brandon Johnson, Ald. David More, and DPD Celebrate Re-opening of the Mat Laundromat in Englewood
- Chicago: Mayor Brandon Johnson Cuts Ribbon on Austin United Alliance Apartments, Bringing 78 Mixed-Income Homes to Austin's Soul City Corridor
"Artificial intelligence has the potential to advance precision medicine in ways that seemed unimaginable just a few short years ago," said Eric Lefkofsky, Founder and CEO of Tempus. "We look forward to working with AstraZeneca to apply AI-enabled solutions to advance its robust therapeutic pipeline in an effort to help patients live longer and healthier lives."
"Cancer drug discovery and clinical development are being transformed by the ability to analyze vast amounts of rich data using artificial intelligence," said Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca. "We are very pleased to collaborate with Tempus to enhance our data-driven R&D strategy and glean critical insights that will deepen our understanding of complex tumor biology, enhance access to predictive preclinical models, and increase the probability of clinical success across our diverse pipeline."
About Tempus
More on illi News
- Shelter Structures America makes European debut at TEMPOR EXPO 2026 in Fulda, Germany
- Johnnie Mandela Releases THOUGHT in the Age of AI
- MAZ6R CLAN & Riviera Marketing: 9/11, 25 - Years Later - "A Creative Response to Tragedy!"
- CodeAutomation Expands U.S. Footprint to Meet Growing Demand for AI and Automation Solutions
- HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Contacts
Erin Carron
erin.carron@tempus.com
Filed Under: Business
0 Comments
Latest on illi News
- Naperville: Police Investigate Report of Gunshots
- Aerostratospheric Adds xAirship and Other Shop Test Units to Its xPrototypes Bench
- Firebox Encapsulator Introduces a New Approach to Fireplace Restoration
- Merlin's Pet Therapy Wrap Introduces a Versatile Approach to Hot and Cold Therapy for Dogs
- Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
- Patented NogginLOC Technology Offers an Innovative Approach to Helmet Fastening
- Mandeville Pests May Pose Serious Health Risks for Your Family
- City of Chicago Partners With Chicago River Swim to Re-Launch "The Big Jump," Expand Field to 750 Swimmers
- Mayor Brandon Johnson and Chicago Public Schools Extend Chicago Connected Program for 2026–27 School Year
- Hardwood Flooring vs Carpet Comparison: Premier Custom Hardwood Flooring Releases Ultimate Buyer's Guide
- The Kryder Law Group, LLC Recovers $1,350,000 in Two Motorcycle Accident Settlements
- Share your workplace safety solutions at 2027 Applied Ergonomics Conference
- Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89
- May The Worst Team Win! Loserball Kicks Off Another NFL Season of Hilarious Mayhem
- Inkdnylon Expands Into Large-Volume Apparel, Uniform and Branded Merchandise Procurement
- Black Women Living With, and Impacted by, HIV Express Gratitude, Grief, Joy, and Resilience
- MainConcept Easy Video API Extends Full Transcoding to Arm and NETINT VPUs
- Aerostratospheric Announces xSatellite Flight Layer And September 12 x1Albatross Engineering Test
- Indie Author & Publishing News Website Launches!
- Cruxy shortlisted for two Private Equity Wire® US Awards 2026: Advisory Firm of the Year (Overall) & Value Creation Consulting Firm of the Year